Gossamer Bio, Inc.: directors' dealings · United States · SEC (Form 4)

About Gossamer Bio, Inc.

Gossamer Bio, Inc. (NASDAQ: GOSS) is a United States-based, clinical-stage biopharmaceutical company headquartered in San Diego, California. The company was founded in 2015, originally as FSG Bio, Inc., and was later launched publicly in 2018 by former Receptos executives. From the outset, Gossamer Bio built its strategy around a combination of in-licensing, clinical development, and targeted therapeutic innovation for areas of high unmet medical need. Today, the company is far more focused than in its early years: its core story is centered on seralutinib, an investigational drug candidate aimed primarily at pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). From a business-model perspective, Gossamer Bio remains a classic development-stage biotech rather than a diversified commercial pharmaceutical company. Its value proposition depends heavily on the clinical, regulatory, and eventual commercial progress of seralutinib. That concentration creates meaningful upside if the asset succeeds, but it also leaves the equity highly exposed to binary clinical outcomes and regulatory decisions. The company emphasizes its scientific foundation in immunology, translational research, and rare-disease development, supported by a management team with deep biotech and pharma experience. In competitive terms, Gossamer Bio operates in a specialist segment of pulmonary medicine where differentiation depends on efficacy, safety, dosing convenience, and the ability to show clear clinical benefit in rare and difficult-to-treat diseases. A key strategic milestone was its global collaboration with Chiesi Group, which was designed to deepen and accelerate development efforts around seralutinib and support future commercialization potential. More recently, however, the investment case became significantly more complex after Gossamer reported topline Phase 3 PROSERA results in February 2026, and the study did not meet its primary endpoint in PAH. That outcome materially changed the market’s perception of the program and introduced a new phase of strategic and regulatory uncertainty. Gossamer Bio trades on the NASDAQ market in the United States, and the stock is highly sensitive to clinical data releases, funding needs, and insider or institutional activity. For investors, the name should be viewed as a high-risk, event-driven biotechnology exposure, where the key drivers are scientific validation, regulatory optionality, and the company’s ability to navigate a rapidly evolving risk profile.